CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $59,000, lower than 95% of all stocks globally
- PositionOperating margin is -134164.4%, lower than 95% of its Biotechnology peers (median -23.8%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.02BUSDvs all stocks (USD)
Revenue (TTM)
59.00KUSDvs all stocks (USD)
Beta
0.7890xvs all stocks
52-Week Change
187.82%vs all stocks
Market Capitalization
1.02BUSDvs all stocks (USD)
Enterprise Value
893.43MUSDvs all stocks (USD)
Forward P/E
-6.47xvs Biotechnology peers
Price to Book (MRQ)
6.45xvs Biotechnology peers
Enterprise to EBITDA
-11.32xvs Biotechnology peers
Return on Assets (TTM)
-41.50%vs Biotechnology peers
Return on Equity (TTM)
-88.76%vs Biotechnology peers
Revenue (TTM)
59.00KUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0040USDUpdated Jul 18, 2026Quarterly Revenue Growth
-100.00%vs Biotechnology peers
Gross Profit (TTM)
-39.52MUSDvs all stocks (USD)
EBITDA (TTM)
-78.93MUSDvs all stocks (USD)
Net Income (TTM)
-84.74MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-59.69MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-23.25MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Revenue
59.00KUSDFY2025 · Dec 31, 2025Cost of Goods Sold
0.00USDFY2025 · Dec 31, 2025Gross Profit
59.00KUSDFY2025 · Dec 31, 2025Operating Income
-72.92MUSDvs all stocks (USD)
Pre-tax Income
-78.09MUSDFY2025 · Dec 31, 2025Income Tax Expense
165.00KUSDFY2025 · Dec 31, 2025Net Income
-78.26MUSDFY2025 · Dec 31, 2025EBIT
-72.92MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-63.06MUSDFY2025 · Dec 31, 2025Research & Development
50.08MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
22.90MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-78.26MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-65.05MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
16.11MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-78.26MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
344.00KUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
165.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
13.62MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-690.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
0.00USDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-146.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-87.00KUSDFY2025 · Dec 31, 2025Net Acquisitions
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-113.72MUSDFY2025 · Dec 31, 2025Sale of Investments
32.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-81.72MUSDFY2025 · Dec 31, 2025Other Financing Charges
-972.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
13.79MUSDFY2025 · Dec 31, 2025Shares Outstanding
24.64MSharesUpdated Jul 18, 2026Shares Short
12.31MSharesUpdated Jul 18, 2026Short Ratio
5.86daysvs all stocks
Short % of Shares Outstanding
23.45%vs all stocks
% Held by Insiders
1.73%vs all stocks
% Held by Institutions
76.07%vs all stocks
Total Cash (MRQ)
81.99MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.56USDUpdated Jul 18, 2026Total Debt (MRQ)
328.00KUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0048xvs Biotechnology peers
Current Ratio (MRQ)
7.66xvs Biotechnology peers
Book Value per Share (MRQ)
2.77USDUpdated Jul 18, 2026Total Assets
116.46MUSDvs all stocks (USD)
Total Current Assets
105.29MUSDFY2025 · Dec 31, 2025Total Liabilities
33.41MUSDFY2025 · Dec 31, 2025Total Non-current Assets
11.17MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
20.47MUSDFY2025 · Dec 31, 2025Total Current Liabilities
12.94MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
15.86MUSDFY2025 · Dec 31, 2025Other Short-term Investments
82.48MUSDFY2025 · Dec 31, 2025Accounts Payable
137.00KUSDFY2025 · Dec 31, 2025Short-term Debt
392.00KUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
2.04MUSDFY2025 · Dec 31, 2025Common Stock (Book)
18.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-448.52MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
83.05MUSDvs all stocks (USD)
52-Week Low
6.21USDUpdated Jul 18, 202652-Week High
24.27USDUpdated Jul 18, 202652-Week Change
187.82%vs all stocks
Beta
0.7890xvs all stocks
50-Day MA
17.03USDUpdated Jul 18, 2026200-Day MA
16.20USDUpdated Jul 18, 2026Avg 10-Day Volume
1.15MSharesUpdated Jul 18, 2026Avg 30-Day Volume
1.83MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-5.57USDUpdated Jul 18, 2026Other Income / Expense
-9.52MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -134164.4%, lower than 95% of its Biotechnology peers (median -23.8%)Significant
Operating margin: -1,341.644Industry median: -0.24Industry P5: -32.91Peers compared: 197
Financial Health
Altman Z-Score 11.78: safe zoneNotable
Altman Z-Score: 11.78
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $59,000, lower than 95% of all stocks globallySignificant
Revenue (USD): 59,000Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Hainan Haiyao Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Edan Instruments Inc.
Tier 1ProductionApproval-Gated PipelineRule
BioAge Labs, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Guangyuyuan Chinese Herbal Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pacira BioSciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Ausun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jiangsu Aidea Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cisen Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Olema Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Suzhou Highfine Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow